Please login to the form below

Not currently logged in
Email:
Password:

CMPT announces CEO and loan investment

CMP Therapeutics has announced that Dr Neill Moray Mackenzie will become CEO and that the company will receive a €1.5m convertible loan investment

CMP Therapeutics (CMPT) has appointed Dr Neill Moray Mackenzie to the role of CEO, replacing Dr Bruce Savage, who leaves CMPT to concentrate on his other portfolio companies.

Dr Mackenzie brings to CMPT experience at executive board level in both the biotechnology and pharmaceutical industries. He has held roles at Cambridge Genetics, Oxford Biomedica, Avidex (now Immunocore) and, most recently, was senior vice president for business development and corporate strategy at Medigene and CEO of Roji (London).

Dr MacKenzie was also a departmental head in vaccine R&D at Wellcome and a Wellcome Lecturer in immunology at the University of London.

In addition, CMPT has announced that the company will receive an injection of €1.5m in the form of a convertible loan from Inventages Venture Capital, which will be used to support continuing operations and the upcoming clinical trial of its lead product for the common cold.

Since 2005 CMPT has been supported solely by investments from London-based Inventages Venture Capital and New Zealand-based BioPacificVentures.

2nd August 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics